COMPANY OVERVIEW

Innocrin is a privately held, clinical-stage pharmaceutical company that discovers and develops novel, best-in-class oral selective inhibitors of CYP17 lyase, a validated target for the treatment of advanced breast and prostate cancer.

---

LOCATION

---

THERAPEUTIC AREAS

Oncology

---

WEBSITE

https://innocrinpharma.com

---

CAREER WEBSITE

https://innocrinpharma.org/contact-us/careers/

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

Jun 20, 2017

Innocrin Pharmaceuticals, Inc. Granted SME Status Designation by the European Medicines Agency

Apr 6, 2017

Innocrin Pharmaceuticals Appoints Fred Eshelman, PharmD as CEO and is Granted Fast Track Designation by FDA for Seviteronel Treatment of Women with Triple-negative Breast Cancer and Women or Men with Estrogen Receptor-positive Breast Cancer

Dec 13, 2016

Innocrin Pharmaceuticals Presents Data from the Ongoing Phase 2 Trial of Seviteronel in Estrogen Receptor-positive or Triple-negative Breast Cancer (CLARITY-01) at the San Antonio Breast Cancer Symposium

Oct 5, 2016

Innocrin Pharmaceuticals, Inc. Appoints Edwina Baskin-Bey, MD as Chief Medical Officer and Expands the Ongoing Phase 2 Study of Seviteronel in Women with Estrogen Receptor-positive or Triple-negative Breast Cancer (TNBC)

May 12, 2016

Innocrin Pharmaceuticals, Inc. Begins Phase 2 Study of Seviteronel in Women with Estrogen Receptor-positive or Triple-negative Breast Cancer and Expands Two Phase 2 Studies of Seviteronel in Men with Metastatic Castrate-resistant Prostate Cancer

For More Press Releases

---